Innovation: it’s in our DNA.
We have always worked across disciplines and geographies to drive scientific discovery and redefine what is possible to improve patients’ lives.

We are working on understanding how diseases differ down to the molecular level. So we can develop new tests and medicines that prevent, diagnose and treat diseases that matter and bring them to the patients who need them. With our combined strengths in diagnostics and pharmaceuticals, our personalised healthcare strategy aims to fit the right treatment to the right patient.

As the world’s largest biotech company, we develop breakthrough medicines, improving the standard-of-care across oncology, immunology, infectious diseases, ophthalmology and neuroscience. We are also the world leader in the \textit{in vitro} diagnostics business. This track record allows us to build lasting and meaningful partnerships across the world with research academia and public healthcare institutions.

The founding families continue to hold the majority stake in the company. This stability allows for a tradition of sustainable thinking, so we can learn from setbacks and focus on lasting value for patients and society. We remain dedicated to the highest standards of quality, safety and integrity. Our legacy is based on respect for the individual, as well as the communities and the world we live in.

- **Who we are**

- **Innovation: it’s in our DNA.**
- **We have always worked across disciplines and geographies to drive scientific discovery and redefine what is possible to improve patients’ lives.**
- **We are working on understanding how diseases differ down to the molecular level. So we can develop new tests and medicines that prevent, diagnose and treat diseases that matter and bring them to the patients who need them.**
- **With our combined strengths in diagnostics and pharmaceuticals, our personalised healthcare strategy aims to fit the right treatment to the right patient.**
- **As the world’s largest biotech company, we develop breakthrough medicines, improving the standard-of-care across oncology, immunology, infectious diseases, ophthalmology and neuroscience.**
- **We are also the world leader in the \textit{in vitro} diagnostics business. This track record allows us to build lasting and meaningful partnerships across the world with research academia and public healthcare institutions.**
- **The founding families continue to hold the majority stake in the company. This stability allows for a tradition of sustainable thinking, so we can learn from setbacks and focus on lasting value for patients and society. We remain dedicated to the highest standards of quality, safety and integrity. Our legacy is based on respect for the individual, as well as the communities and the world we live in.**

- **Who we are | Roche Roche | Who we are**

- **91,747 employees in over 100 countries**
- **CHF 48.1 bn in Group sales in 2015**
- **# 1 in biotech, oncology, in vitro diagnostics and hospital market**
- **29 Roche medicines on the WHO Essential Medicines List**
What we do

We are a research-based, global healthcare company with combined strengths in pharmaceuticals and diagnostics.

We develop, manufacture and deliver innovative medicines and diagnostic instruments and tests that help millions of patients globally. With a clear set of priorities, we aim to achieve sustainable growth and deliver value to all of our stakeholders.

We conducted a materiality analysis in 2014 at the corporate level amongst our key stakeholders to map out the most important topics related to these priorities.

As a result, we identified 21 material topics that stood out as highly relevant to us and to our key stakeholders, with a significant economic, environmental or social impact. These material topics are reflected in our business priorities and we have concrete actions related to them in our operational activities.*

Focus on patients
- Disease awareness and treatment education
- Patient organisation support
- Drug efficacy, safety and counterfeiting
- Biosimilar safety

Excellence in science
- Product portfolio strategy
- Patent policies
- Data transparency on clinical trials

Personalised healthcare
- R&D pipeline strategy and personalised healthcare

Access to healthcare
- Sustainable healthcare
- Growth strategy in emerging and developed markets
- Pricing

Great workplace
- Employee engagement and talent retention
- Compensation/benefits
- Leadership commitments
- Organisational effectiveness
- Executive compensation

Sustainable value
- Environmental responsibility
- Compliance
- Occupational accidents
- Community engagement
- Supply chain management

* For more information about our materiality process and outcomes, see www.roche.com/materiality
## 2015 highlights

<table>
<thead>
<tr>
<th>Month</th>
<th>Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>EU approval of <strong>Avastin</strong> in advanced cervical cancer</td>
</tr>
<tr>
<td></td>
<td>EU approval of <strong>Perjeta</strong> regimen in early breast cancer</td>
</tr>
<tr>
<td></td>
<td>FDA breakthrough therapy designation for <strong>atezolizumab</strong> in a type of lung cancer</td>
</tr>
<tr>
<td></td>
<td>Positive phase II results for <strong>atezolizumab</strong> in advanced bladder cancer</td>
</tr>
<tr>
<td>December</td>
<td>FDA breakthrough therapy designation for <strong>emicizumab</strong> (ACE910) in hemophilia A</td>
</tr>
<tr>
<td></td>
<td>First national <strong>HPV primary screening</strong> tender won in Europe</td>
</tr>
<tr>
<td></td>
<td>Positive phase III results for <strong>Gazyva/Gazyvaro</strong> in a type of non-Hodgkin lymphoma and leukemia</td>
</tr>
<tr>
<td></td>
<td>US and EU approval of <strong>Cotellic plus Zelboraf</strong> in advanced melanoma</td>
</tr>
</tbody>
</table>

### 2015 highlights

- Partnership with **Foundation Medicine** on molecular information
- FDA breakthrough therapy designation for **venetoclax** in two forms of leukemia
- Launch of first Roche **PCR liquid biopsy test**
- FDA clearance for **cobas flu A/B test** for use on our cobas Liat-System
- Positive phase III results for **ocrelizumab** in two forms of multiple sclerosis
- FDA approval for **cobas HBV, cobas HCV and cobas HCV viral load tests**
- **Carbon Disclosure Project** recognition on climate change mitigation
- US approval of **Alecensa** in a type of lung cancer

- US approval of **Lucentis** in diabetic retinopathy
- FDA breakthrough therapy designation for **Actemra** in systemic sclerosis
- **FDA breakthrough therapy designation for venetoclax** in two forms of leukemia
- **FDA breakthrough therapy designation for eteplizumab** in multiple sclerosis
- **FDA breakthrough therapy designation for Actemra** in systemic sclerosis
Financial performance

In 2015, sales grew strongly across our two divisions. Pharmaceuticals Division sales increased by 5%,* driven by oncology medicines Herceptin, Avastin and Perjeta as well as Esbriet for idiopathic pulmonary fibrosis. Diagnostics Division sales grew by 6%, driven primarily by immunodiagnostic products. This enabled us to post net income of CHF 9.1 billion, despite the substantial appreciation of the Swiss franc.

Thanks to our strong business performance we are able to further enhance our innovation capabilities and deliver healthcare solutions which make a difference in patients’ lives.

CHF 48.1 billion Group sales
+5% growth

CHF 17.5 billion core operating profit
+5% growth

CHF 9.1 billion IFRS net income
+4% growth

CHF 13.49 core earnings per share
+7% growth**

* All growth rates are at constant exchange rates (average 2014). ** Excluding the one-time benefit of CHF 428 million before tax related to the divestment of filgrastim rights in 2014.
Innovation

Research and development highlights
We made significant progress with our product pipeline, launching new medicines as well as diagnostics solutions. In 2015, we obtained five major approvals and four FDA breakthrough therapy designations on our medicines.

For our investigational medicine ocrelizumab, we announced strong data in both relapsing and primary progressive forms of multiple sclerosis. In addition, we presented promising results for our lead investigational cancer immunotherapy medicine atezolizumab in bladder and lung cancer. We also received EU and US approval for Cotellic plus Zelboraf to treat metastatic melanoma, and US approval for the cancer medicine Alecensa for a specific form of lung cancer.

CHF 9.3 billion
Group investments in R&D
19.4%* of sales

70 new molecular entities
in clinical development

4 FDA breakthrough therapy designations
granted for Roche medicines in 2015

324,380 patients
participating in clinical trials

* All growth rates are at constant exchange rates (average 2014).

In Diagnostics, we further extended our industry-leading product portfolio with seven test and eight instrument launches, including new cobas 6800 and cobas 8800 systems in Molecular Diagnostics and the Ventana HE 600 system in Tissue Diagnostics.

Strategic partnerships to improve patient care
In January 2016, we announced a partnership with Flatiron Health, an industry leader in realworld oncology data. Building on the collaboration with Foundation Medicine, begun in 2015, this agreement is another important milestone to drive our leadership in personalised healthcare. Highquality healthcare data and advanced analytics will improve both the development of medicines and the quality of treatment decisions.

In 2015, we also acquired Ariosa Diagnostics, Signature Diagnostics, CAPP Medical and Kapa Biosystems, companies with strong expertise and technologies which will complement our activities aimed at building a next-generation sequencing portfolio.
Sustainability

We run our business in a way that is ethical and aims to create long-term value for all stakeholders. We create value developing medical solutions and we aim for as many people to benefit from them as possible. We believe that our success lies in our ability to develop strategies where both industry and society benefit in a sustainable way.

Access to healthcare

Universal access to medical innovation and quality healthcare remains a global challenge. That challenge is complex and multifaceted. Healthcare resources and the demands on those resources vary widely from country to country, and even within countries. In some regions, the most sophisticated new medicines and diagnostic tests are readily available, whilst in others, the healthcare infrastructure is so limited that basic medical care is still a luxury.

Our aim is for every person who needs our products to be able to access and benefit from them. For this to happen, several conditions need to be in place, including disease awareness, adequate healthcare infrastructure and sufficient medical coverage. We are committed to working with our stakeholders to improve outcomes across the access spectrum.

7 years running
Roche ranked as the most sustainable healthcare company by the Dow Jones Sustainability Indices

The delivery of quality healthcare is complex and involves a number of stakeholders. We are working with partners at the local level to address the challenges and help establish sustainable solutions.

25 million patients treated with one of our top 25 selling medicines
126 million patients receiving Roche medicines that are now off-patent
>7 million infants have been HIV-tested through a Roche Diagnostics global access programme since 2002
>40,000 patients now have access to Herceptin through Roche’s patient access programme in China
Environmental responsibility
Our aim is to minimise our ecological footprint and to increase the use of renewable resources whilst continuing to expand our global business.

In 2015, we continued to improve our environmental performance, with significant progress in improving our energy efficiency. Several Roche sites invested in state-of-the-art and energy-efficient infrastructure, allowing us to reduce our environmental footprint and reduce costs.

Our efforts in optimising energy consumption and reducing volume of consumed water, as well as emissions to air and an increased headcount contributed to a decrease of our total environmental impact per employee by 3.6% compared to 2014.

Community engagement
We are committed to sustainable philanthropic activities, which span community involvement, humanitarian projects, science, education, art and culture. Our goal is to establish long-term partnerships by focusing on projects that add lasting value to society.

Since 2003, Roche employees have continually raised money to support education programmes for HIV/AIDS orphaned children in Malawi by joining the annual Children’s Walk. Our commitment to Malawi spans over 12 years and has helped to support over 17,000 children in their education.

People
We are committed to cultivating a more diverse talent pipeline across generations, geographies and functional areas of expertise. We are aiming to increase the representation of key leaders with established and developing region experience and provide opportunities for our employees to work in different environments. We are also aiming to increase the representation of women in key leadership positions.

23% of women in key leadership positions
1 in 5 key senior positions are led by people with both established and developing region experience

Recognition by CDP
for our climate change mitigation strategy

15% sustainable energy consumption on track with our 2020 goal of 20%

People
We are committed to cultivating a more diverse talent pipeline across generations, geographies and functional areas of expertise. We are aiming to increase the representation of key leaders with established and developing region experience and provide opportunities for our employees to work in different environments. We are also aiming to increase the representation of women in key leadership positions.

23% of women in key leadership positions
1 in 5 key senior positions are led by people with both established and developing region experience

Community engagement
We are committed to sustainable philanthropic activities, which span community involvement, humanitarian projects, science, education, art and culture. Our goal is to establish long-term partnerships by focusing on projects that add lasting value to society.

Since 2003, Roche employees have continually raised money to support education programmes for HIV/AIDS orphaned children in Malawi by joining the annual Children’s Walk. Our commitment to Malawi spans over 12 years and has helped to support over 17,000 children in their education.

19,000 employees raising about CHF 1.3 million for children in Malawi
Doing now what patients need next

We believe it’s urgent to deliver medical solutions right now—even as we develop innovations for the future. We are passionate about transforming patients’ lives. We are courageous in both decision and action. And we believe that good business means a better world.

That is why we come to work each day. We commit ourselves to scientific rigour, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow.

We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.

We are Roche.
Cautionary statement regarding forward-looking statements

Roche in Brief contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in Roche in Brief, among others:

1. Pricing and product initiatives of competitors;
2. Legislative and regulatory developments and economic conditions;
3. Delay or inability in obtaining regulatory approvals or bringing products to market;
4. Fluctuations in currency exchange rates and general financial market conditions;
5. Uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products;
6. Increased government pricing pressures;
7. Interruptions in production;
8. Loss of or inability to obtain adequate protection for intellectual property rights;
9. Litigation;
10. Loss of key executives or other employees; and
11. Adverse publicity and news coverage.

The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for 2016 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.